Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic

Journal of Clinical Microbiology

Volumn 49, Issue 8, 2011, Pages 3088-3091

  Srivastava, Pankaj ^a   Prajapati, Vijay Kumar ^a   Rai, Madhukar ^a   Sundar, Shyam ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ARGININE; HEMOGLOBIN; LEUCINE; VALINE;

AGED; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CHILL; CONTROLLED STUDY; CYSTEINE PROTEINASE B GENE; DRUG RESPONSE; DRUG TOLERANCE; FEVER; GENE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INDIA; LEISHMANIA DONOVANI; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PALLOR; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; SPLEEN BIOPSY; SPLENOMEGALY; VISCERAL LEISHMANIASIS;

AGED; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CYSTEINE PROTEASES; DRUG RESISTANCE; GENE EXPRESSION PROFILING; HUMANS; INDIA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

LEISHMANIA DONOVANI;

EID: 79960946931     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00173-11     Document Type: Article

References (11)

1. Barnett, P. G., S. P. Singh, C. Bern, A. W. Hightower, and S. Sundar. 2005. Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am. J. Trop. Med. Hyg. 73:720-725.
2. Dey, A., U. Sharma, and S. Singh. 2007. First case of indigenous visceral leishmaniasis from central India. Am. J. Trop. Med. Hyg. 77:95-98.
3. Ellis, D. 2002. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl. 1):7-10.
4. Lachaud, L., et al. 2009. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin. Infect. Dis. 48:16-22.
5. Manandhar, K. D., et al. 2008. Antileishmanial activity of nano-amphotericin B deoxycholate. J. Antimicrob. Chemother. 62:376-380.
6. Prajapati, V. K., et al. 2011. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J. Antimicrob. Chemother. 66:874-879.
7. Quispe Tintaya, K. W., et al. 2004. Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex. J. Infect. Dis. 189:1035-1043.
8. Sharma, N. L., et al. 2009. Characteristics of Leishmania spp. isolated from a mixed focus of cutaneous and visceral leishmaniasis in Himachal Pradesh (India). Internet J. Third World Med. 7:8.
9. Singh, A. K., and P. M. Ouellette. 2001. Gene amplification in amphotericin B resisitance Leishmania tarentolae. Exp. Parasitol. 99:141-147.
10. Sundar, S., et al. 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31:1104-1107.
11. Yardley, V., and S. L. Croft. 2000. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13:243-248.